Browse by author
Lookup NU author(s): Elizabeth Sconce, Professor Ann DalyORCiD, Dr Tayyaba Khan, Dr Hilary Wynne, Professor Farhad Kamali
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Alterations in vitamin K availability can significantly influence anticoagulation response to warfarin. Apolipoprotein E (APOE) plays a part in the hepatic uptake of lipid-soluble vitamin K. This study aimed to determine the influence of common polymorphisms in the APOE gene on warfarin dose requirements. patients with stable anticoagulation control and with a target International Normalized Ratio (INR) 2.0-3.0 were genotyped for the APOE ε2, ε3 and ε4 variants. Mean±SD daily warfarin doses were significantly lower in patients carrying at least one ε4 allele compared to the ε3ε3 reference genotype (3.3±1.9 versus 4.0±1.8; P=0.03; 95% CI: 0.1-1.2). Multivariate regression analysis showed that patient age, height and CYP2C9, VKORC1 and APOE genotypes significantly contributed to warfarin dose requirement (R=57%). only the ε4 allele of APOE was found to make a significant (P=0.002) but small contribution to warfarin dose requirement. There was no significant difference in fasted plasma vitamin K concentration between patients with the different APOE genotypes. This study suggests that APOE genotype is unlikely to have a clinically significant effect on warfarin dose requirements. © 2006 Lippincott Williams & Wilkins.
Author(s): Sconce EA, Daly AK, Khan TI, Wynne HA, Kamali F
Publication type: Article
Publication status: Published
Journal: Pharmacogenetics and Genomics
Year: 2006
Volume: 16
Issue: 8
Pages: 609-611
ISSN (print): 1744-6872
ISSN (electronic): 1744-6880
Publisher: Lippincott Williams & Wilkins
URL: http://dx.doi.org/10.1097/01.fpc.0000220567.98089.b5
DOI: 10.1097/01.fpc.0000220567.98089.b5
PubMed id: 16847429
Altmetrics provided by Altmetric
